Abel Hall LLC’s United Therapeutics UTHR Stock Holding History

Abel Hall LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-413	Closed	-$201K	–	976
2025 Q4	$201K	Buy	+413	New	+$192K	0.05%	542

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Abel Hall LLC's UTHR Position: Q1 2026 in Review

Abel Hall LLC sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 413 shares — an estimated $201K sold.

Abel Hall LLC first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $201K in Q4 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Abel Hall LLC reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
Abel Hall LLC sold 413 United Therapeutics shares in Q1 2026, an estimated $201K.
Abel Hall LLC first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
Abel Hall LLC's United Therapeutics position peaked at $201K in Q4 2025.
854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.